Airway and systemic effects of inhaled corticosteroids in asthma: Dose response relationship

Pulmonary Pharmacology

Volumn 9, Issue 1, 1996, Pages 19-27

  Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; FLUTICASONE;

ADRENAL SUPPRESSION; AIRWAY; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; HYDROCORTISONE RELEASE; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0030088023     PISSN: 09520600     EISSN: None     Source Type: Journal    
DOI: 10.1006/pulp.1996.0002     Document Type: Review

References (48)

1. 1. British Thoracic Society. Guidelines for the management of asthma: a summary. Br Med J 1993; 306: 776-782.
2. 2. Johannsson S A, Anderson F E, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982; 22: 523-529.
3. 3. Anderson N, Klint S, Randwall G, Wiren J E. Equipotency of budesonide and fluticasone propionate in the vasoconstrictor assay. Thorax 1994; 49: 422P.
4. 4. Phillips G H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 19-23.
5. 5. English A F, Neate M S, Quint D J, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994; 149 (Suppl.): A212.
6. 6. Randwall G, Klint S, Soderblom M, Larsson P, Andersson N, Lindgren S. Topical activity of glucocorticosteroids in the vasoconstriction assay: method comparison. Eur Respir J 1994; 7 (Suppl. 18): 381S.
7. 7. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
8. 8. Miller-Larsson A, Mattsson H, Ohlsson S, Hjertberg E, Tunek A, Dahlback M, Brattsand R. Prolonged release from the airway tissue from glucocorticoids budesonide and fluticasone propionate as compared to beclomethasone dipropionate. Am J Respir Crit Care Med 1994; 149 (Suppl. 4): A466.
9. 9. Thorsson L, Edsbacker S, Conradson T B. Lung deposition of budesonide from turbuhaler is twice that from pressurized metered-dose inhaler (pMDI). Eur Respir J 1994; 7: 1839-1844.
10. 10. Ryrfeldt A, Anderson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63 (Suppl. 122): 86-95.
11. 11. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996, in press.
12. 12. Grahnen A, Eckernas S A, Brundin R M, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521-525.
13. 13. Würthwein G, Rehder S, Rodewald P. Lipophilicty andaffinity of glucocorticoids. Pharm Ztg Wiss 1992; 4: 161-167.
14. 14. Toogood J H, Lefcoe N M, Haines D S M, Jennings B, Errington N, Baksh L, Chuang L. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1977; 59: 298-308.
15. 15. Toogood J H, Baskerville J, Jennings B, Lefcoe N M, Johansson S A. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 668-670.
16. 16. Lipworth B J. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmac Ther 1993; 58: 173-209.
17. 17. Dahl R, Lundback B, Malo J L, Mazza J A, Nieminen M M, Saarelainen P, Barnade T. Dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
18. 18. Boe J, Bakke P, Rodolen T, Skovlund E, Gulsvik A. High dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994; 7: 2179-2184.
19. 19. Ayres J G, Bateman E D, Lundback B, Harris T A J. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-586.
20. 20. Fabbri L, Burge P S, Croonenburgh L, Warlies F, Weeke B, Ciaccia A, Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993; 48: 817-833.
21. 21. Barnes N C, Marone G, Di Maria G U, Visser S, Utama I, Payne S I. A comparison of fluticasone propionate, 1 mg, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877-884.
22. 22. Lundback B, Alexander M, Day J, Herbert J, Holzer R, Van Uffelen R, Kesten S, Jones A L. Evaluation of fluticasone propionate (500 mg/day) administered either as dry powder via a diskhaler inhaler or pressurized inhaler and compared with beclomethasone type propionate (1000 μg/day) administered by pressurized inhaler. Respir Med 1993; 87: 609-620.
23. 23. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
24. 24. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radfin M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
25. 25. Harding S M. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 25-29.
26. 26. Lipworth B J. New perspectives on inhaled drug delivery and systemic bioactivity (Editorial). Thorax 1995; 50: 105-110.
27. 27. Trescoli-Serrano C, Ward M J, Rajput R, Garcia-Zorco M. Does swallowing charcoal affect gastrointestinal absorption of inhaled beclomethasone. Eur Respir J 1995; 8 (Suppl. 19): S304.
28. 28. Grove A, Allam C, McFarlane L C, McPhate G, Jackson C M, Lipworth B J. A comparison of systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38: 527-532.
29. 29. Lonnebo A, Grahnen A, Jansson B, Ling-Anderson A, Brundin R M, Eckernas S A. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 459-463.
30. 30. Dogterom P, Oosterhuis B, Ebels J T, Jonkman J H G. Inhaled fluticasone propionate induces greater cortisol suppression compared to budesonide. A dose-response study using pressurised metered dose-inhalers. Eur Respir J 1995; 8 (Suppl. 19): 303S.
31. 31. Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262-266.
32. 2-adrenoceptor function in asthmatic patients. Chest 1996; 109: 343-347.
33. 33. Jennings B H, Anderson K E, Johansson S A. Assessment of systemic effects of inhaled glucocorticoids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77-82.
34. 34. Clark D J, Clark R A, Lipworth B J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer in asthmatic children. Thorax 1996; in press.
35. 35. Pedersen S, Fugslang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988; 1: 433-435.
36. 36. Wolthers O D, Pedersen S. Measures of systemic activity of inhaled corticosteroids in children: a comparison of urine cortisol excretion and knemometry. Respir Med 1995; 89: 347-349.
37. 37. Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31: 579-582.
38. 38. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
39. 39. Russell G. Asthma and growth. Arch Dis Child 1993; 69: 695-698.
40. 40. Grove A, McFarlane L C, Jackson C M, Lipworth B J. Effects of short-term exposure to high dose inhaled corticosteroids on novel markers of bone metabolism. Eur J Clin Pharmacol 1996; in press.
41. 41. Kerstjens H A B, Postma D, van Doormaal J J, van Lanlen A K, Brand P L P, Dekhuijzen P N R, Koeter G H. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airway obstruction. Thorax 1994; 49: 652-656.
42. 42. Toogood J H, Baskerville J, Jennings B, Lefcoe N M, Johansson S A. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis 1983; 129: 723-729.
43. 43. Pedersen S, Steffensen G, Ohlsson S V. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a turbuhaler. Br J Clin Pharmacol 1993; 36: 201-214.
44. 44. Brown P H, Blundell G, Greening A P, Crompton G K. Do large volume spacer devices reduce systemic effects of high dose inhaled corticosteroids. Thorax 1990; 45: 736-739.
45. 45. Toogood J H, Baskerville J, Jennings B, Lefcoe N M, Johansson S A. Influence of the dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid budesonide. J Allergy Clin Immunol 1982; 70: 288-298.
46. 46. Malo J L, Cartier A, Merland N, Ghezzo O H, Burek A, Morris J, Jennings B. Four times a day dosing frequency is better than twice-a-day regimen in subjects who required a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis 1989; 190: 624-628.
47. 47. Jones A H, Langdon C G, Lee P S, Linghams S A, Nankan J P, Follows R M A, Tollemar U, Richardson P D T. Pulmicort turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293-299.
48. 48. Gagnon M, Cole J, Milot J, Turcotte H, Boulet L P. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest 1994; 105: 1732-1734.